124 related articles for article (PubMed ID: 21658343)
1. Treatment-resistant depression: prevalence, risk factors, and treatment strategies.
Thase ME
J Clin Psychiatry; 2011 May; 72(5):e18. PubMed ID: 21658343
[TBL] [Abstract][Full Text] [Related]
2. Depression: Managing Resistance and Partial Response to Treatment.
Gaddey HL; Mason B; Naik A
Am Fam Physician; 2024 May; 109(5):410-416. PubMed ID: 38804755
[TBL] [Abstract][Full Text] [Related]
3. Efficacy of combined, sequential and crossover psychotherapy and pharmacotherapy in improving outcomes in depression.
Segal Z; Vincent P; Levitt A
J Psychiatry Neurosci; 2002 Jul; 27(4):281-90. PubMed ID: 12174737
[TBL] [Abstract][Full Text] [Related]
4. Older adults with severe, treatment-resistant depression.
Unützer J; Park M
JAMA; 2012 Sep; 308(9):909-18. PubMed ID: 22948701
[TBL] [Abstract][Full Text] [Related]
5. Optimizing the Treatment of Late-Life Depression.
Walaszek A
Am J Psychiatry; 2024 Jan; 181(1):7-10. PubMed ID: 38161301
[No Abstract] [Full Text] [Related]
6. Treatment-resistant depression: definitions, review of the evidence, and algorithmic approach.
McIntyre RS; Filteau MJ; Martin L; Patry S; Carvalho A; Cha DS; Barakat M; Miguelez M
J Affect Disord; 2014 Mar; 156():1-7. PubMed ID: 24314926
[TBL] [Abstract][Full Text] [Related]
7. Risk factors for treatment resistance in unipolar depression: a systematic review.
Bennabi D; Aouizerate B; El-Hage W; Doumy O; Moliere F; Courtet P; Nieto I; Bellivier F; Bubrovsky M; Vaiva G; Holztmann J; Bougerol T; Richieri R; Lancon C; Camus V; Saba G; Haesbaert F; d'Amato T; Charpeaud T; Llorca PM; Leboyer M; Haffen E
J Affect Disord; 2015 Jan; 171():137-41. PubMed ID: 25305428
[TBL] [Abstract][Full Text] [Related]
8. Treatment-resistant depression: therapeutic trends, challenges, and future directions.
Al-Harbi KS
Patient Prefer Adherence; 2012; 6():369-88. PubMed ID: 22654508
[TBL] [Abstract][Full Text] [Related]
9. The integrative management of treatment-resistant depression: a comprehensive review and perspectives.
Carvalho AF; Berk M; Hyphantis TN; McIntyre RS
Psychother Psychosom; 2014; 83(2):70-88. PubMed ID: 24458008
[TBL] [Abstract][Full Text] [Related]
10. Management of treatment-resistant depression.
Keitner GI; Mansfield AK
Psychiatr Clin North Am; 2012 Mar; 35(1):249-65. PubMed ID: 22370501
[TBL] [Abstract][Full Text] [Related]
11. Definition and epidemiology of treatment-resistant depression.
Fava M; Davidson KG
Psychiatr Clin North Am; 1996 Jun; 19(2):179-200. PubMed ID: 8827185
[TBL] [Abstract][Full Text] [Related]
12. Efficacy and Safety of Intranasal Esketamine Adjunctive to Oral Antidepressant Therapy in Treatment-Resistant Depression: A Randomized Clinical Trial.
Daly EJ; Singh JB; Fedgchin M; Cooper K; Lim P; Shelton RC; Thase ME; Winokur A; Van Nueten L; Manji H; Drevets WC
JAMA Psychiatry; 2018 Feb; 75(2):139-148. PubMed ID: 29282469
[TBL] [Abstract][Full Text] [Related]
13. Efficacy and Safety of Intranasal Esketamine for the Rapid Reduction of Symptoms of Depression and Suicidality in Patients at Imminent Risk for Suicide: Results of a Double-Blind, Randomized, Placebo-Controlled Study.
Canuso CM; Singh JB; Fedgchin M; Alphs L; Lane R; Lim P; Pinter C; Hough D; Sanacora G; Manji H; Drevets WC
Am J Psychiatry; 2018 Jul; 175(7):620-630. PubMed ID: 29656663
[TBL] [Abstract][Full Text] [Related]
14. Efficacy and safety of vortioxetine (Lu AA21004), 15 and 20 mg/day: a randomized, double-blind, placebo-controlled, duloxetine-referenced study in the acute treatment of adult patients with major depressive disorder.
Boulenger JP; Loft H; Olsen CK
Int Clin Psychopharmacol; 2014 May; 29(3):138-49. PubMed ID: 24257717
[TBL] [Abstract][Full Text] [Related]
15. Personality traits as risk factors for treatment-resistant depression.
Takahashi M; Shirayama Y; Muneoka K; Suzuki M; Sato K; Hashimoto K
PLoS One; 2013; 8(5):e63756. PubMed ID: 23717477
[TBL] [Abstract][Full Text] [Related]
16. Defining treatment-resistant depression.
Gaynes BN; Lux L; Gartlehner G; Asher G; Forman-Hoffman V; Green J; Boland E; Weber RP; Randolph C; Bann C; Coker-Schwimmer E; Viswanathan M; Lohr KN
Depress Anxiety; 2020 Feb; 37(2):134-145. PubMed ID: 31638723
[TBL] [Abstract][Full Text] [Related]
17. Defining treatment-resistant depression: a comprehensive review of the literature.
Trevino K; McClintock SM; McDonald Fischer N; Vora A; Husain MM
Ann Clin Psychiatry; 2014 Aug; 26(3):222-32. PubMed ID: 25166485
[TBL] [Abstract][Full Text] [Related]
18. Real-world data analysis of the clinical and economic burden and risk factors in patients with major depressive disorder with an inadequate response to initial antidepressants.
Park H; Park CM; Woo JM; Shin JY; Lee EK; Kwon SH
J Med Econ; 2021; 24(1):589-597. PubMed ID: 33879031
[TBL] [Abstract][Full Text] [Related]
19. Treatment-resistant major depressive disorder: Canadian expert consensus on definition and assessment.
Rybak YE; Lai KSP; Ramasubbu R; Vila-Rodriguez F; Blumberger DM; Chan P; Delva N; Giacobbe P; Gosselin C; Kennedy SH; Iskandar H; McInerney S; Ravitz P; Sharma V; Zaretsky A; Burhan AM
Depress Anxiety; 2021 Apr; 38(4):456-467. PubMed ID: 33528865
[TBL] [Abstract][Full Text] [Related]
20. Augmentation with Atypical Antipsychotics for Treatment-Resistant Depression.
Cantù F; Ciappolino V; Enrico P; Moltrasio C; Delvecchio G; Brambilla P
J Affect Disord; 2021 Feb; 280(Pt A):45-53. PubMed ID: 33202337
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
